Sancuso was Cumberland Pharmaceuticals’s largest product and service line in fiscal 2025, bringing in $11.91M of $44.52M (27%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Product | — | — | — | — | ||||||
| Kristalose | $15.21M | $15.98M | $15.32M | $10.54M | ||||||
| Sancuso | $13.21M | $8.10M | $9.01M | $11.91M | ||||||
| Vibativ | $7.49M | $8.81M | $7.16M | $9.48M | ||||||
| Caldolor | $4.83M | $4.33M | $4.96M | $4.66M | ||||||
| Product - Talicia | — | — | — | $3.31M | ||||||
| Product - Other | — | — | $1.33M | $4.13M | ||||||
| Other | $1.33M | $2.04M | — | — | ||||||
| Acetadote | $501.04K | $458.76K | $185.18K | $508.17K | ||||||
| Omeclamox | — | $20.03K | -$3.08K | -$10.44K | ||||||
| Omeclamox-Pak | $29.15K | — | — | — | ||||||
| Reditrex | -$126.73K | -$341.89K | $90.24K | $11.39K | ||||||
| Vaprisol | -$447.70K | $151.34K | -$174.54K | -$18.35K | ||||||
| Total | $42.01M | $39.55M | $37.87M | $44.52M |
Cumberland Pharmaceuticals brought in $44.52M from its 10 product and service lines in fiscal 2025, the year ended December 31, 2025. Cumberland Pharmaceuticals regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $37.87M. Sancuso was the largest at $11.91M (26.7%), ahead of Kristalose at $10.54M (23.7%) and Vibativ at $9.48M (21.3%). The other five lines brought in $12.62M combined.
Compared with fiscal 2024, Product - Other grew fastest, up 210.1% to $4.13M, while Kristalose fell the most, down 31.2% to $10.54M.
Cumberland Pharmaceuticals began breaking out Product - Talicia in fiscal 2025, Product - Other in fiscal 2024 and Omeclamox in fiscal 2023. Cumberland Pharmaceuticals stopped reporting Other ($2.04M in fiscal 2023) and Omeclamox-Pak ($29.15K in fiscal 2022) as separate lines. The total is net of Omeclamox, which took $10.44K off revenue in fiscal 2025.
Cumberland Pharmaceuticals (CPIX) reports its revenue by product and service. In fiscal 2025, Sancuso was its largest product and service line, bringing in $11.91M (26.7% of the total), followed by Kristalose at $10.54M (23.7%).
Sancuso was Cumberland Pharmaceuticals' largest product and service line in fiscal 2025, bringing in $11.91M, or 26.7% of the $44.52M total across its 10 product and service lines.
Every figure comes from Cumberland Pharmaceuticals' annual financial filings, as reported. Each line keeps the name Cumberland Pharmaceuticals gives it, and years follow its fiscal calendar.
Cumberland Pharmaceuticals' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.